Resources

Amici Procurement Solutions Rebrands as MyAmici. The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, end-to-end LabOps platform supporting biotech, medtech, and life-science organisations across every stage of growth.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

Pioneer Group, a specialist in life science infrastructure and venture building, and global biopharmaceutical company AbbVie, have crowned Alceus Bio the winner of their 2025 Golden Ticket programme.

NRG Therapeutics Ltd has announced that the first participants have been dosed in its first-in-human Phase 1 clinical trial of its lead candidate NRG5051 being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.

Engitix announced the closing of a $25 million Series A extension financing, by Netherton Investments, a fund investing on behalf of Mike Platt.

EnteroBiotix Limited announced positive final results from for EBX-102-02, a therapeutic for irritable bowel syndrome with constipation and diarrhoea.

Relation and healthcare investment firm Deerfield Management, a current investor,  has launched a new research collaboration to advance therapeutic discovery projects for diseases of high unmet need.

Coulter Partners completed a search assignment for Alethio Therapeutics, placing Dr. Rohit Batta as Chief Executive Officer.

Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.

Dark Blue Therapeutics, a discovery and development biotech company pioneering the next generation of precision oncology medicines, has been acquired by Amgen.

Happy New Year to all our BIA members and collaborators. We hope that the break has provided an opportunity for a refresh, ready for a jam-packed 2026. Many of you will be heading to JPM – don't miss the UK reception.

Working closely with BIA’s FTAC and HMRC, FTI Consulting have devoted a great deal of time interpreting the new legislation for qualifying overseas expenditure and guidance.

Brainomix, a global leader and pioneer of AI-powered imaging biomarkers for stroke and lung fibrosis, has announced results from its partnership with Argenica Therapeutics for imaging and clinical data analysis of the Phase II trial evaluating ARG-007, a neuroprotective agent for acute ischemic stroke.

In this blog, Matej Metkovic, CEO and Founder of Wasteless Bio, explores the valuable unused equipment sitting in labs that quietly erodes in worth.

Minister for Skills Baroness Jacqui Smith chose Precision Health Technology Accelerator (PHTA) as the setting for the launch of a new Higher Technical Qualification (HTQ) designed to tackle the UK’s growing medtech skills shortage.

As 2025 draws to a close, the UK life sciences and biotech sector looks back on a year of challenge, progress, collaboration and impact. From funding headwinds and policy uncertainty to major fundraising achievements, government commitments and rising global confidence in the UK, BIA highlights the key developments shaping the sector and sets the stage for a strong 2026.

eXmoor Pharma and UCL have launched a new partnership to strengthen the pathway from academic research to GMP delivery, giving UCL innovators earlier access to CMC expertise, development capabilities and clinical manufacturing support to accelerate the translation of cell and gene therapies.

Proceeds will enable generation of full clinical data from ongoing Phase 1 study of TROCEPT-01 (ATTR-01), its lead programme in advanced solid tumours, and progression of TROCEPT-02 (ATTR-02) into the clinic.

In this blog, Blood Cancer UK reflects on a year of partnership with BIA — from raising vital funds and forging new connections in life sciences, to amplifying the voice of people affected by blood cancer across the UK.

Precision treatments tackling the hardest-to-treat cancers set to be produced from hundreds of tonnes of reprocessed uranium from nuclear reactors